Trinity Biotech plc (TRIB)

1,5300 +0,0100 (+0,66 %) À partir de 01:59PM EDT. Marché ouvert.

Trinity Biotech plc

IDA Business Park
Bray A98 H5C8
Ireland
353 1 276 9800
https://www.trinitybiotech.com

Secteur(s): Healthcare
Secteur d’activité: Diagnostics & Research
Employés à temps plein: 380

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. John Gillard	President, CEO, Company Secretary & Director	710k	S.O.	1981
Mr. Ronan O'Caoimh	Founder, Director & Executive Advisor	80k	S.O.	1956
Dr. James Walsh Ph.D.	Executive Director of Business Development & Executive Director	50k	S.O.	1958
Mr. Des Fitzgerald	Interim Chief Financial Officer	S.O.	S.O.	1990
Ms. Jacqueline O'Neill	Director of Operations	S.O.	S.O.	1973
Mr. Simon Dunne	Chief Accounting Officer	S.O.	S.O.	1974
Dr. Gary Keating Ph.D.	Chief Technology Officer	S.O.	S.O.	1973
Ms. Eibhlin Kelly	Chief Information Officer	S.O.	S.O.	1984
Mr. Colm Molloy	Group Director of Human Resources & Culture	S.O.	S.O.	1971

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Trinity Biotech plc acquires, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Trinity Biotech plc en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.